pH‐Responsive Isoprenoid‐Antitumoral Polymer Conjugates for Superior Drug Loading via Self‐Assembly and Endosomal‐Targeted Anticancer Activity
ChemMedChem · 2026-01 · 21 (2)
DOI: 10.1002/cmdc.202500810 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 31.01.2026. Verfasst von Camilla Passi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Pharmaceutical Materials and Processing, Saarland University, Campus C4 1, 66123, Saarbrücken, Germany. Hauptthemen laut MEDLINE: Antineoplastic Agents, Endosomes, Polymers, Farnesol. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 104 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Polymer‐drug conjugates (PDCs) are a promising strategy to enhance the delivery of poorly soluble drugs, particularly in cancer therapy. By improving solubility and enabling site‐specific accumulation, PDCs minimize systemic toxicity while maximizing therapeutic efficacy. PDCs often employ stimuli‐responsive linkers, such as Schiff's bases, to achieve controlled drug release in tumor microenvironments or acidic intracellular compartments. In this study, we designed a novel PDC by conjugating the anticancer agent farnesal (Far) to ∈‐Poly‐L‐Lysine (PL) via an imine bond, without using additional linkers. PL is a natural, biodegradable, water‐soluble polymer with inherent anticancer properties, while Far is a hydrophobic isoprenoid with potent antitumor activity. The conjugate (Far‐PL) displayed pH‐responsive behavior, remaining stable at physiological pH but releasing drugs under acidic tumor (pH 6.5) and endosomal (pH 5.5) conditions. Far‐PL exhibited enhanced cytotoxicity against A549 lung cancer cells compared to its components alone, while showing reduced toxicity towards noncancerous cells (Arlo cells). The amphiphilicity allows the conjugate to self‐assemble into stable nanoparticles with a positive surface charge, narrow size distribution, and 100% drug content—clearly exceeding conventional nanoparticles (5–10 wt%). This effective PDC design demonstrates strong potential to maximize tumor‐selective activity while minimizing off‐target effects, offering a promising platform for future cancer therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Pharmaceutical Materials and Processing, Saarland University, Campus C4 1, 66123, Saarbrücken, Germany.
- Department of Pharmacy, Biopharmaceutics and Pharmaceutical Technology, Saarland University, Campus C4 1, 66123, Saarbrücken, Germany.
- PharmaScienceHub (PSH), Saarland University, Campus E2 1, 66123, Saarbrücken, Germany.
- Helmholtz Institute of Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research (HZI), Campus E8 1, 66123, Saarbrücken, Germany.
ORCID-Profile: Nicole Schneider-Daum, Marc Schneider, Sangeun Lee
Zitieren
APA
Passi, C., Neu, T., Schneider-Daum, N., Lehr, C. M., Schneider, M., & Lee, S. (2026). pH‐Responsive Isoprenoid‐Antitumoral Polymer Conjugates for Superior Drug Loading via Self‐Assembly and Endosomal‐Targeted Anticancer Activity. ChemMedChem, 21(2). https://doi.org/10.1002/cmdc.202500810
Vancouver
Passi C, Neu T, Schneider-Daum N, Lehr CM, Schneider M, Lee S. pH‐Responsive Isoprenoid‐Antitumoral Polymer Conjugates for Superior Drug Loading via Self‐Assembly and Endosomal‐Targeted Anticancer Activity. ChemMedChem. 2026;21(2). doi:10.1002/cmdc.202500810
BibTeX
@article{Passi2026,
author = {Passi, Camilla and Neu, Tobias and Schneider-Daum, Nicole and Lehr, Claus-Michael and Schneider, Marc and Lee, Sangeun},
title = {pH‐Responsive Isoprenoid‐Antitumoral Polymer Conjugates for Superior Drug Loading via Self‐Assembly and Endosomal‐Targeted Anticancer Activity},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {2},
doi = {10.1002/cmdc.202500810}
}
EUVIMED